374 related articles for article (PubMed ID: 31948289)
61. Trimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease.
Fennema D; Phillips IR; Shephard EA
Drug Metab Dispos; 2016 Nov; 44(11):1839-1850. PubMed ID: 27190056
[TBL] [Abstract][Full Text] [Related]
62. Trimethylamine But Not Trimethylamine Oxide Increases With Age in Rat Plasma and Affects Smooth Muscle Cells Viability.
Jaworska K; Konop M; Hutsch T; Perlejewski K; Radkowski M; Grochowska M; Bielak-Zmijewska A; Mosieniak G; Sikora E; Ufnal M
J Gerontol A Biol Sci Med Sci; 2020 Jun; 75(7):1276-1283. PubMed ID: 31411319
[TBL] [Abstract][Full Text] [Related]
63. Role of the Gut Microbiome in the Development of Atherosclerotic Cardiovascular Disease.
Al Samarraie A; Pichette M; Rousseau G
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982492
[TBL] [Abstract][Full Text] [Related]
64. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls.
Unger MM; Spiegel J; Dillmann KU; Grundmann D; Philippeit H; Bürmann J; Faßbender K; Schwiertz A; Schäfer KH
Parkinsonism Relat Disord; 2016 Nov; 32():66-72. PubMed ID: 27591074
[TBL] [Abstract][Full Text] [Related]
65. Gut microbiota-derived short-chain fatty acids and colorectal cancer: Ready for clinical translation?
Hou H; Chen D; Zhang K; Zhang W; Liu T; Wang S; Dai X; Wang B; Zhong W; Cao H
Cancer Lett; 2022 Feb; 526():225-235. PubMed ID: 34843863
[TBL] [Abstract][Full Text] [Related]
66. Trimethylamine N-oxide: A harmful, protective or diagnostic marker in lifestyle diseases?
Nowiński A; Ufnal M
Nutrition; 2018 Feb; 46():7-12. PubMed ID: 29290360
[TBL] [Abstract][Full Text] [Related]
67. TMAO: how gut microbiota contributes to heart failure.
Zhang Y; Wang Y; Ke B; Du J
Transl Res; 2021 Feb; 228():109-125. PubMed ID: 32841736
[TBL] [Abstract][Full Text] [Related]
68. Effect of Short Chain Fatty Acids on Age-Related Disorders.
Fernandes MF; de Oliveira S; Portovedo M; Rodrigues PB; Vinolo MAR
Adv Exp Med Biol; 2020; 1260():85-105. PubMed ID: 32304031
[TBL] [Abstract][Full Text] [Related]
69. Immunomodulatory Effects of Microbiota-Derived Short-Chain Fatty Acids in Autoimmune Liver Diseases.
Zhang W; Mackay CR; Gershwin ME
J Immunol; 2023 Jun; 210(11):1629-1639. PubMed ID: 37186939
[TBL] [Abstract][Full Text] [Related]
70. Gut microbiota-derived trimethylamine-N-oxide: A bridge between dietary fatty acid and cardiovascular disease?
He M; Tan CP; Xu YJ; Liu Y
Food Res Int; 2020 Dec; 138(Pt B):109812. PubMed ID: 33288187
[TBL] [Abstract][Full Text] [Related]
71. Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: A randomized controlled trial.
Cho CE; Taesuwan S; Malysheva OV; Bender E; Tulchinsky NF; Yan J; Sutter JL; Caudill MA
Mol Nutr Food Res; 2017 Jan; 61(1):. PubMed ID: 27377678
[TBL] [Abstract][Full Text] [Related]
72. Trimethylamine
Canyelles M; Tondo M; Cedó L; Farràs M; Escolà-Gil JC; Blanco-Vaca F
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347638
[TBL] [Abstract][Full Text] [Related]
73. Metabolite profiling reveals the interaction of chitin-glucan with the gut microbiota.
Rodriguez J; Neyrinck AM; Zhang Z; Seethaler B; Nazare JA; Robles Sánchez C; Roumain M; Muccioli GG; Bindels LB; Cani PD; Maquet V; Laville M; Bischoff SC; Walter J; Delzenne NM
Gut Microbes; 2020 Nov; 12(1):1810530. PubMed ID: 32893709
[TBL] [Abstract][Full Text] [Related]
74. Trimethylamine N-oxide (TMAO) as a New Potential Therapeutic Target for Insulin Resistance and Cancer.
Oellgaard J; Winther SA; Hansen TS; Rossing P; von Scholten BJ
Curr Pharm Des; 2017; 23(25):3699-3712. PubMed ID: 28641532
[TBL] [Abstract][Full Text] [Related]
75. Interrelation between gut microbiota, SCFA, and fatty acid composition in pigs.
Sebastià C; Folch JM; Ballester M; Estellé J; Passols M; Muñoz M; García-Casco JM; Fernández AI; Castelló A; Sánchez A; Crespo-Piazuelo D
mSystems; 2024 Jan; 9(1):e0104923. PubMed ID: 38095419
[TBL] [Abstract][Full Text] [Related]
76. The gut-blood barrier permeability - A new marker in cardiovascular and metabolic diseases?
Ufnal M; Pham K
Med Hypotheses; 2017 Jan; 98():35-37. PubMed ID: 28012600
[TBL] [Abstract][Full Text] [Related]
77. Higher Fecal Short-Chain Fatty Acid Levels Are Associated with Gut Microbiome Dysbiosis, Obesity, Hypertension and Cardiometabolic Disease Risk Factors.
de la Cuesta-Zuluaga J; Mueller NT; Álvarez-Quintero R; Velásquez-Mejía EP; Sierra JA; Corrales-Agudelo V; Carmona JA; Abad JM; Escobar JS
Nutrients; 2018 Dec; 11(1):. PubMed ID: 30591685
[TBL] [Abstract][Full Text] [Related]
78. Gut microbiota in atherosclerosis: focus on trimethylamine N-oxide.
Zhu Y; Li Q; Jiang H
APMIS; 2020 May; 128(5):353-366. PubMed ID: 32108960
[TBL] [Abstract][Full Text] [Related]
79. [Research Progress of Short Chain Fatty Acids in the Pathogenesis of Immune Thrombocytopenia--Review].
Li XN; Qu W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1296-1300. PubMed ID: 35981402
[TBL] [Abstract][Full Text] [Related]
80. Short Chain Fatty Acids Taken at Time of Thrombectomy in Acute Ischemic Stroke Patients Are Independent of Stroke Severity But Associated With Inflammatory Markers and Worse Symptoms at Discharge.
Henry N; Frank J; McLouth C; Trout AL; Morris A; Chen J; Stowe AM; Fraser JF; Pennypacker K
Front Immunol; 2021; 12():797302. PubMed ID: 35126360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
